Tvardi Therapeutics Inc. (TVRD) has disclosed a new risk, in the Accounting & Financial Operations category.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tvardi Therapeutics Inc. faces significant financial challenges as it continues to incur substantial net losses, with no approved products for commercial sale and a reliance on equity and debt financing. The company is in the early stages of developing its biopharmaceutical product candidates, including TTI-101, which is only in Phase 2 clinical trials for hepatocellular carcinoma and has not met its goals in a recent IPF study. Tvardi’s accumulated deficit of $103.2 million as of September 2025 underscores the speculative nature of its endeavors, and the company anticipates increased expenses as it advances its pipeline and infrastructure. The path to profitability remains uncertain, with the potential for continued losses even if some product candidates eventually receive marketing approval.
Overall, Wall Street has a Moderate Buy consensus rating on TVRD stock based on 3 Buys and 4 Holds.
To learn more about Tvardi Therapeutics Inc.’s risk factors, click here.